DCF Advisers LLC Has $231,000 Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

DCF Advisers LLC raised its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 22.4% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 17,750 shares of the company’s stock after acquiring an additional 3,250 shares during the quarter. DCF Advisers LLC’s holdings in Viridian Therapeutics were worth $231,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Ameritas Investment Partners Inc. boosted its holdings in shares of Viridian Therapeutics by 19.2% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,961 shares of the company’s stock valued at $87,000 after buying an additional 799 shares during the last quarter. Swiss National Bank boosted its stake in Viridian Therapeutics by 1.2% in the 4th quarter. Swiss National Bank now owns 67,200 shares of the company’s stock valued at $1,464,000 after purchasing an additional 800 shares during the period. Principal Financial Group Inc. increased its position in Viridian Therapeutics by 9.7% during the 1st quarter. Principal Financial Group Inc. now owns 11,915 shares of the company’s stock worth $209,000 after buying an additional 1,058 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Viridian Therapeutics by 4.1% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 28,822 shares of the company’s stock worth $505,000 after buying an additional 1,135 shares in the last quarter. Finally, Arizona State Retirement System boosted its position in shares of Viridian Therapeutics by 14.7% in the second quarter. Arizona State Retirement System now owns 13,178 shares of the company’s stock valued at $171,000 after acquiring an additional 1,688 shares during the period.

Insider Activity at Viridian Therapeutics

In other Viridian Therapeutics news, Director Fairmount Funds Management Llc bought 1,600,000 shares of Viridian Therapeutics stock in a transaction on Friday, September 13th. The shares were purchased at an average cost of $18.75 per share, with a total value of $30,000,000.00. Following the acquisition, the director now directly owns 3,445,813 shares of the company’s stock, valued at approximately $64,608,993.75. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.65% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and set a $44.00 price target on shares of Viridian Therapeutics in a research report on Thursday. Oppenheimer reiterated an “outperform” rating and set a $28.00 price target (down previously from $31.00) on shares of Viridian Therapeutics in a research report on Monday, August 12th. Wedbush restated an “outperform” rating and set a $42.00 price objective on shares of Viridian Therapeutics in a research report on Monday, July 29th. The Goldman Sachs Group raised their target price on Viridian Therapeutics from $25.00 to $31.00 and gave the company a “buy” rating in a report on Thursday, September 12th. Finally, Wolfe Research initiated coverage on Viridian Therapeutics in a report on Tuesday, June 11th. They set an “outperform” rating and a $29.00 price target for the company. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $35.30.

Viridian Therapeutics Stock Up 6.8 %

Shares of VRDN opened at $22.50 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 15.82 and a current ratio of 15.82. Viridian Therapeutics, Inc. has a 52 week low of $10.93 and a 52 week high of $24.18. The stock has a market capitalization of $1.44 billion, a price-to-earnings ratio of -5.00 and a beta of 1.03. The stock has a fifty day moving average of $15.93 and a 200-day moving average of $15.05.

Viridian Therapeutics (NASDAQ:VRDN) last posted its earnings results on Thursday, August 8th. The company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.15). The firm had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.09 million. Viridian Therapeutics had a negative net margin of 79,185.77% and a negative return on equity of 83.18%. As a group, sell-side analysts anticipate that Viridian Therapeutics, Inc. will post -3.93 earnings per share for the current fiscal year.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.